Found: 12
Select item for more details and to access through your institution.
Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a<sub>1</sub> receptor) antagonist.
- Published in:
- Pharmacology Research & Perspectives, 2023, v. 11, n. 4, p. 1, doi. 10.1002/prp2.1112
- By:
- Publication type:
- Article
Reactive electrophilic oxylipins trigger a heat stress-like response through HSFA1 transcription factors.
- Published in:
- Journal of Experimental Botany, 2016, v. 67, n. 21, p. 6139, doi. 10.1093/jxb/erw376
- By:
- Publication type:
- Article
Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 9, p. 1365, doi. 10.3390/biom13091365
- By:
- Publication type:
- Article
Pharmacokinetics, pharmacodynamics and safety of the novel C‐X‐C chemokine receptor 3 antagonist ACT‐777991: Results from the first‐in‐human study in healthy adults.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 2, p. 588, doi. 10.1111/bcp.15914
- By:
- Publication type:
- Article
A Clinical Drug‐Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 106, n. 6, p. 1398, doi. 10.1002/cpt.1564
- By:
- Publication type:
- Article
Response to "Impact of Acute Alcohol Exposure on P‐Glycoprotein Function at the Blood–Brain Barrier Assessed Using <sup>11</sup>C‐Metoclopramide PET Imaging".
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P‐Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 104, n. 6, p. 1249, doi. 10.1002/cpt.1083
- By:
- Publication type:
- Article
Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-69326-y
- By:
- Publication type:
- Article
Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y<sub>12</sub> Receptor Antagonist Selatogrel in Healthy Subjects.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 5, p. 687, doi. 10.1007/s40262-021-01097-9
- By:
- Publication type:
- Article
A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 8, p. 1906, doi. 10.1111/cts.13298
- By:
- Publication type:
- Article
First‐in‐human study with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients.
- Published in:
- Basic & Clinical Pharmacology & Toxicology, 2022, v. 131, n. 2, p. 114, doi. 10.1111/bcpt.13756
- By:
- Publication type:
- Article